Therapie des aktiven Morbus Crohn mit dem Boswellia-serrata-Extrakt H 15

Gerhardt, H.; Seifert, Frank; Buvari, P.; Vogelsang, Harald; Repges, Rudolf

doi:10.1055/s-2001-10708

Cited by 201 publications

(106 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have been able to confirm the anti-inflammatory properties of these compounds in an experimental model of colitis in rats (21). Furthermore, recent clinical trials with formulations containing boswellic acids have demonstrated some effectiveness in the treatment of asthma, osteoarthritis, and inflammatory bowel diseases (IBD) (12,14,15,20). Although these clinical studies have drawn attention to boswellic acids as potentially powerful anti-inflammatory drugs, little progress has been made in defining the mechanisms that underlie the beneficial effects of these agents.…”

mentioning

confidence: 57%

Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis

Anthoni

Laukoetter²,

Rijcken³

et al. 2006

American Journal of Physiology-Gastrointestinal and Liver Physi

107

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 57%

Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis

Anthoni

Laukoetter²,

Rijcken³

et al. 2006

American Journal of Physiology-Gastrointestinal and Liver Physi

107

View full text Add to dashboard Cite

show abstract

“…11 In clinical research, positive effects of boswellic acids in the treatment of inflammatory diseases could be shown. 3,12 There exist clinical trials about the use of boswellic acids in asthma, 13 rheumatoid arthritis, 14 Crohn disease, 15 collagenous colitis, 16 and osteoarthritis of the knee. 17,18 To our knowledge, there exist only first clinical observation results for the treatment of cerebral edema by boswellic acids.…”

Section: Discussionmentioning

confidence: 99%

Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors

Kirste

Treier

Wehrle

et al. 2011

Cancer

119

View full text Add to dashboard Cite

BACKGROUND:Patients irradiated for brain tumors often suffer from cerebral edema and are usually treated with dexamethasone, which has various side effects. To investigate the activity of Boswellia serrata (BS) in radiotherapyrelated edema, we conducted a prospective, randomized, placebo-controlled, double-blind, pilot trial. METHODS: Forty-four patients with primary or secondary malignant cerebral tumors were randomly assigned to radiotherapy plus either BS 4200 mg/day or placebo. The volume of cerebral edema in the T2-weighted magnetic resonance imaging (MRI) sequence was analyzed as a primary endpoint. Secondary endpoints were toxicity, cognitive function, quality of life, and the need for antiedematous (dexamethasone) medication. Blood samples were taken to analyze the serum concentration of boswellic acids (AKBA and KBA). RESULTS: Compared with baseline and if measured immediately after the end of radiotherapy and BS/placebo treatment, a reduction of cerebral edema of >75% was found in 60% of patients receiving BS and in 26% of patients receiving placebo (P ¼ .023). These findings may be based on an additional antitumor effect. There were no severe adverse events in either group. In the BS group, 6 patients reported minor gastrointestinal discomfort. BS did not have a significant impact on quality of life or cognitive function. The dexamethasone dose during radiotherapy in both groups was not statistically different. Boswellic acids could be detected in patients' serum. CONCLUSIONS: BS significantly reduced cerebral edema measured by MRI in the study population. BS could potentially be steroid-sparing for patients receiving brain irradiation. Our findings will need to be further validated in larger studies. Cancer 2011;117:3788-

show abstract

“…Boswellia serrata contains four important BAs: a-boswellic acid, b-boswellic acid, 11-ketob-boswellic acid (KBA), and 3-acetyl-11-keto-b-boswellic acid (AKBA) (Singh et al, 1996). The gum resin is established to possess potent anti-inflammatory activity in traditional ayurvedic medicines (Ammon, 2006) and also used in other diseases like, joint pain (Sharma et al, 1989;Gupta et al, 1994;Kimmatkar et al, 2003), tumor (Huang et al, 2000), colitis (Gupta et al, 2001), hyperlipidemia (Pandey et al, 2005), crohn's illness (Gerhardt et al, 2001), etc.…”

Section: Introductionmentioning

confidence: 99%

Development and optimization of boswellic acid-loaded proniosomal gel

2016

View full text Add to dashboard Cite

Context: Boswellic acids (BAs) are isolated from oleo gum of Boswellia serrata and are mainly used as potential anti-inflammatory, hypolipidemic, immunomodulatory, and antitumor agents. Pharmacokinetic investigations of BAs uncover its poor bioavailability through digestive system thus creates a need for improved therapeutic responses which can possibly be achieved by developing formulations through novel delivery system. Objective: Present study was conducted to design topical BA-loaded proniosomal gel for the management of inflammatory disorders with enhanced bioavailability. Materials and methods: Nonionic surfactant vesicles were prepared using the coacervation phase separation method. A central composite design was employed to statistically optimize formulation variables using Design-Expert software. Three independent variables were evaluated: amount of surfactant (X 1 ), amount of soya lecithin (X 2 ), and amount of cholesterol (X 3 ). The encapsulation efficiency percentage (Y 1 ) and particle size (Y 2 ) were selected as dependent variables. Results and discussion: The optimum formulation (F10) displayed spherical bi-layered vesicles under transmission electron microscopy with optimum particle size of 707.9 nm and high entrapment efficiency as 98.52%. In vitro skin permeation study demonstrated the most sustained release of 84.83 ± 0.153 mg/cm 2 in 24 h. Anti-inflammatory activity of the gel showed a significant (p 5 0.001) higher percentage inhibition as compared to the marketed gel at the same dose. Conclusion: The present study exhibited that BA-loaded proniosomal gel was better in terms of absorption, bioavailability, and release kinetics.

show abstract

Therapie des aktiven Morbus Crohn mit dem Boswellia-serrata-Extrakt H 15

Cited by 201 publications

References 1 publication

Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis

Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis

Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors

Development and optimization of boswellic acid-loaded proniosomal gel

Contact Info

Product

Resources

About